Search

Your search keyword '"Glogova, Evgenia"' showing total 40 results
Start Over Author "Glogova, Evgenia"
40 results on '"Glogova, Evgenia"'

1. Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia: Long-term results of the AIEOP-BFM ALL 2000 trial in Austria

Author

Ronceray, Leila, Dworzak, Michael, Dieckmann, Karin, Ebetsberger-Dachs, Georg, Glogova, Evgenia, Haas, Oskar A., Jones, Neil, Nebral, Karin, Moser, Reinhard, Lion, Thomas, Meister, Bernhard, Panzer-Grümayer, Renate, Strehl, Sabine, Peters, Christina, Pötschger, Ulrike, Urban, Christian, Mann, Georg, and Attarbaschi, Andishe

Published
2024
Full Text
View/download PDF

2. Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial

Author

Eichinger, Anna, Poetschger, Ulrike, Glogova, Evgenia, Bader, Peter, Basu, Oliver, Beier, Rita, Burkhardt, Birgit, Classen, Carl-Friedrich, Claviez, Alexander, Corbacioglu, Selim, Deubzer, Hedwig E., Greil, Johann, Gruhn, Bernd, Güngör, Tayfun, Kafa, Kinan, Kühl, Jörn-Sven, Lang, Peter, Lange, Bjoern Soenke, Meisel, Roland, Müller, Ingo, Sauer, Martin G., Schlegel, Paul-Gerhardt, Schulz, Ansgar, Stachel, Daniel, Strahm, Brigitte, Wawer, Angela, Peters, Christina, and Albert, Michael H.

Published
2022
Full Text
View/download PDF

3. Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study Group

Author

Pichler, Herbert, primary, Sedlacek, Petr, additional, Meisel, Roland, additional, Beier, Rita, additional, Faraci, Maura, additional, Kalwak, Krzysztof, additional, Ifversen, Marianne, additional, Müller, Ingo, additional, Stein, Jerry, additional, Vettenranta, Kim, additional, Kropshofer, Gabriele, additional, Kolenova, Alexandra, additional, Karlhuber, Susanne, additional, Glogova, Evgenia, additional, Poetschger, Ulrike, additional, Peters, Christina, additional, Suttorp, Meinolf, additional, Matthes‐Leodolter, Susanne, additional, and Balduzzi, Adriana, additional

Published
2024
Full Text
View/download PDF

4. Solid Tumours

Author

Ladenstein, Ruth, Glogova, Evgenia, Lanza, Francesco, Carreras, Enric, editor, Dufour, Carlo, editor, Mohty, Mohamad, editor, and Kröger, Nicolaus, editor

Published
2019
Full Text
View/download PDF

5. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

Author

Dalle, Jean-Hugues, Balduzzi, Adriana, Bader, Peter, Pieczonka, Anna, Yaniv, Isaac, Lankester, Arjan, Bierings, Marc, Yesilipek, Akif, Sedlacek, Petr, Ifversen, Marianne, Svec, Peter, Toporski, Jacek, Gungor, Taifun, Wachowiak, Jacek, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina

Published
2021
Full Text
View/download PDF

6. Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study

Author

Balduzzi, Adriana, Dalle, Jean-Hugues, Wachowiak, Jacek, Yaniv, Isaac, Yesilipek, Akif, Sedlacek, Petr, Bierings, Marc, Ifversen, Marianne, Sufliarska, Sabina, Kalwak, Krzysztof, Lankester, Arjan, Toporski, Jacek, Di Maio, Lucia, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina

Published
2019
Full Text
View/download PDF

7. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes

Author

Dalle, Jean-Hugues, Balduzzi, Adriana, Bader, Peter, Lankester, Arjan, Yaniv, Isaac, Wachowiak, Jacek, Pieczonka, Anna, Bierings, Marc, Yesilipek, Akif, Sedlaçek, Petr, Ifversen, Marianne, Sufliarska, Sabina, Toporski, Jacek, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina

Published
2018
Full Text
View/download PDF

8. Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL

Author

Babor, Florian, Peters, Christina, Manser, Angela R., Glogova, Evgenia, Sauer, Martin, Pötschger, Ulrike, Ahlmann, Martina, Cario, Gunnar, Feuchtinger, Tobias, Gruhn, Bernd, Güngör, Tayfun, Horn, Peter A., Kremens, Bernhard, Lang, Peter, Mezger, Markus, Müller, Ingo, Mytilineos, Joannis, Oevermann, Lena, Pichler, Herbert, Scherenschlich, Nadine, Schuster, Friedhelm R., Siepermann, Meinolf, Stachel, Daniel, Strahm, Brigitte, Wössmann, Wilhelm, Escherich, Gabriele, Zimmermann, Martin, Schrappe, Martin, Borkhardt, Arndt, Eckert, Cornelia, Bader, Peter, Uhrberg, Markus, and Meisel, Roland

Published
2019
Full Text
View/download PDF

9. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy

Author

Lode, Holger N., primary, Ladenstein, Ruth, additional, Troschke-Meurer, Sascha, additional, Struppe, Linda, additional, Siebert, Nikolai, additional, Zumpe, Maxi, additional, Ehlert, Karoline, additional, Huber, Stefanie, additional, Glogova, Evgenia, additional, Hundsdoerfer, Patrick, additional, Eggert, Angelika, additional, Zaniewska-Tekieli, Anna, additional, Balwierz, Walentyna, additional, and Wieczorek, Aleksandra, additional

Published
2023
Full Text
View/download PDF

11. Solid Tumours

Author

Ladenstein, Ruth, primary, Glogova, Evgenia, additional, and Lanza, Francesco, additional

Published
2018
Full Text
View/download PDF

13. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL‐SCT 2003/2007 trial

Author

Kuhlen, Michaela, Willasch, Andre M., Dalle, Jean‐Hugues, Wachowiak, Jacek, Yaniv, Isaac, Ifversen, Marianne, Sedlacek, Petr, Guengoer, Tayfun, Lang, Peter, Bader, Peter, Sufliarska, Sabina, Balduzzi, Adriana, Strahm, Brigitte, von Luettichau, Irene, Hoell, Jessica I., Borkhardt, Arndt, Klingebiel, Thomas, Schrappe, Martin, von Stackelberg, Arend, Glogova, Evgenia, Poetschger, Ulrike, Meisel, Roland, and Peters, Christina

Published
2018
Full Text
View/download PDF

15. Incidence of Secondary Malignancies after Total Body Irradiation-Based Allogeneic HSCT in Children with ALL – Long-Term Follow-up from the Prospective ALL-SCT 2003 Trial

Author

Eichinger, Anna, primary, Glogova, Evgenia, additional, Poetschger, Ulrike, additional, Bader, Peter, additional, Basu, Oliver, additional, Beier, Rita, additional, Burkhardt, Birgit, additional, Classen, Carl-Friedrich, additional, Claviez, Alexander, additional, Corbacioglu, Selim, additional, Deubzer, Hedwig, additional, Greil, Johann, additional, Gruhn, Bernd, additional, Gungor, Tayfun, additional, Kafa, Kinan, additional, Lang, Peter, additional, Lange, Bjoern Soenke, additional, Mueller, Ingo, additional, Sauer, Martin G., additional, Schlegel, Paul-Gerhard, additional, Schulz, Ansgar, additional, Stachel, Klaus Daniel, additional, Strahm, Brigitte R., additional, Wawer, Angela, additional, Kühl, Jörn-Sven, additional, Meisel, Roland, additional, Peters, Christina, additional, and Albert, Michael H., additional

Published
2022
Full Text
View/download PDF

18. Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia—A prospective international multicenter trial on behalf of the BFM‐SG and the EBMT‐PDWP

Author

Pichler, Herbert, Lawitschka, Anita, Glogova, Evgenia, Willasch, Andre M., Luettichau, Irene von, Lehrnbecher, Thomas, Matthes-Martin, Susanne, Lang, Peter, Bader, Peter, Sykora, Karl W., Schrum, Johanna, Kremens, Bernhard, Ehlert, Karoline, Albert, Michael H., Kuhlen, Michaela, Meisel, Roland, Guengoer, Tayfun, Strahm, Brigitte, Gruhn, Bernd, Schulz, Ansgar, Woessmann, Wilhelm, Poetschger, Ulrike, Peters, Christina, and Luettichau, Irene

Subjects
Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Medizin, Hematopoietic stem cell transplantation, Gastroenterology, Severity of Illness Index, Multicenter trial, Internal medicine, Medicine, Humans, Transplantation, Homologous, Prospective Studies, Risk factor, Prospective cohort study, Child, Research Articles, business.industry, Incidence, Hazard ratio, Hematopoietic Stem Cell Transplantation, Common Terminology Criteria for Adverse Events, Hematology, Bacterial Infections, Total body irradiation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, ddc, Transplantation, surgical procedures, operative, Mycoses, Virus Diseases, Child, Preschool, Multivariate Analysis, Female, business, Unrelated Donors, Whole-Body Irradiation, Research Article
Abstract

Severe infections (SI) significantly impact on non‐relapse mortality after hematopoietic stem cell transplantation (HSCT). We assessed 432 children and adolescents with acute lymphoblastic leukemia (ALL) after total body irradiation based myeloablative HSCT within the multicenter ALL‐BFM‐SCT 2003 trial for SI grade 3 or higher according to common terminology criteria for adverse events. A total 172 patients experienced at least one SI. Transplantation from matched unrelated donors (MUD) was associated with any type of SI in the pre‐engraftment period (hazard ratio [HR]: 2.57; P

Published
2019

20. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

Author

Dalle, Jean-Hugues; https://orcid.org/0000-0002-8406-0793, Balduzzi, Adriana; https://orcid.org/0000-0002-5879-0610, Bader, Peter, Pieczonka, Anna; https://orcid.org/0000-0001-5922-4242, Yaniv, Isaac, Lankester, Arjan, Bierings, Marc; https://orcid.org/0000-0002-0192-3080, Yesilipek, Akif, Sedlacek, Petr, Ifversen, Marianne, Svec, Peter; https://orcid.org/0000-0002-7647-2253, Toporski, Jacek; https://orcid.org/0000-0001-6012-0651, Güngör, Tayfun; https://orcid.org/0000-0002-3261-1186, Wachowiak, Jacek, Glogova, Evgenia, Poetschger, Ulrike, Peters, Christina; https://orcid.org/0000-0003-0369-8515, Dalle, Jean-Hugues; https://orcid.org/0000-0002-8406-0793, Balduzzi, Adriana; https://orcid.org/0000-0002-5879-0610, Bader, Peter, Pieczonka, Anna; https://orcid.org/0000-0001-5922-4242, Yaniv, Isaac, Lankester, Arjan, Bierings, Marc; https://orcid.org/0000-0002-0192-3080, Yesilipek, Akif, Sedlacek, Petr, Ifversen, Marianne, Svec, Peter; https://orcid.org/0000-0002-7647-2253, Toporski, Jacek; https://orcid.org/0000-0001-6012-0651, Güngör, Tayfun; https://orcid.org/0000-0002-3261-1186, Wachowiak, Jacek, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina; https://orcid.org/0000-0003-0369-8515

Abstract

Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 year old were transplanted after TBI-based MAC. The median follow-up was 5 years. 463 patients were transplanted from matched donor (MD) and 106 from mismatched donor (MMD). 214 were in CR1. Stem cell source was unmanipulated BM for 330 patients, unmanipulated PBSC for 135, ex vivo T-cell depleted PBSC for 62 and cord-blood for 26. There were more advanced disease, more ex vivo T-cell depletion, and more chemotherapy based conditioning regimen for patients transplanted from MMD as compared to those transplanted from MSD or MD. Median follow up (reversed Kaplan Meier estimator) was 4.99 years, median follow up of survivals was 4.88, range (0.01–11.72) years. The 4-year CI of extensive cGvHD was 13 ± 2% and 17 ± 4% (p = NS) for the patients transplanted from MD and MMD, respectively. 4-year EFS was statistically better for patients transplanted from MD (60 ± 2% vs. 42 ± 5%, p < 0.001) for the whole cohort. This difference does not exist if considering separately patients treated in the most recent study. There was no difference in 4-year CI of relapse. The 4-year NRM was lower for patients transplanted from MD (9 ± 1% vs. 23 ± 4%, p < 0.001). In multivariate analysis, donor-type appears as a negative risk-factor for OS, EFS, and NRM. This paper demonstrates the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using MMD stem cell source.

Published
2021

21. Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94

Author

Fiedler, Stefan, primary, Ambros, Inge M., additional, Glogova, Evgenia, additional, Benesch, Martin, additional, Urban, Christian, additional, Mayer, Marlene, additional, Ebetsberger-Dachs, Georg, additional, Bardi, Edit, additional, Jones, Neil, additional, Gamper, Agnes, additional, Meister, Bernhard, additional, Crazzolara, Roman, additional, Amann, Gabriele, additional, Dieckmann, Karin, additional, Horcher, Ernst, additional, Kerbl, Reinhold, additional, Brunner-Herglotz, Bettina, additional, Ziegler, Andrea, additional, Ambros, Peter F., additional, and Ladenstein, Ruth, additional

Published
2021
Full Text
View/download PDF

22. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

Author

Ambros, Inge M., primary, Tonini, Gian-Paolo, additional, Pötschger, Ulrike, additional, Gross, Nicole, additional, Mosseri, Véronique, additional, Beiske, Klaus, additional, Berbegall, Ana P., additional, Bénard, Jean, additional, Bown, Nick, additional, Caron, Huib, additional, Combaret, Valérie, additional, Couturier, Jerome, additional, Defferrari, Raffaella, additional, Delattre, Olivier, additional, Jeison, Marta, additional, Kogner, Per, additional, Lunec, John, additional, Marques, Barbara, additional, Martinsson, Tommy, additional, Mazzocco, Katia, additional, Noguera, Rosa, additional, Schleiermacher, Gudrun, additional, Valent, Alexander, additional, Van Roy, Nadine, additional, Villamon, Eva, additional, Janousek, Dasa, additional, Pribill, Ingrid, additional, Glogova, Evgenia, additional, Attiyeh, Edward F., additional, Hogarty, Michael D., additional, Monclair, Tom F., additional, Holmes, Keith, additional, Valteau-Couanet, Dominique, additional, Castel, Victoria, additional, Tweddle, Deborah A., additional, Park, Julie R., additional, Cohn, Sue, additional, Ladenstein, Ruth, additional, Beck-Popovic, Maja, additional, De Bernardi, Bruno, additional, Michon, Jean, additional, Pearson, Andrew D. J., additional, and Ambros, Peter F., additional

Published
2020
Full Text
View/download PDF

23. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

Author

Dalle, Jean-Hugues, primary, Balduzzi, Adriana, additional, Bader, Peter, additional, Pieczonka, Anna, additional, Yaniv, Isaac, additional, Lankester, Arjan, additional, Bierings, Marc, additional, Yesilipek, Akif, additional, Sedlacek, Petr, additional, Ifversen, Marianne, additional, Svec, Peter, additional, Toporski, Jacek, additional, Gungor, Taifun, additional, Wachowiak, Jacek, additional, Glogova, Evgenia, additional, Poetschger, Ulrike, additional, and Peters, Christina, additional

Published
2020
Full Text
View/download PDF

24. Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia—A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP

Author

Pichler, Herbert; https://orcid.org/0000-0001-5107-5123, Lawitschka, Anita, Glogova, Evgenia, Willasch, Andre M, et al, Güngör, Tayfun; https://orcid.org/0000-0002-3261-1186, Pichler, Herbert; https://orcid.org/0000-0001-5107-5123, Lawitschka, Anita, Glogova, Evgenia, Willasch, Andre M, et al, and Güngör, Tayfun; https://orcid.org/0000-0002-3261-1186

Abstract

Severe infections (SI) significantly impact on non-relapse mortality after hematopoietic stem cell transplantation (HSCT). We assessed 432 children and adolescents with acute lymphoblastic leukemia (ALL) after total body irradiation based myeloablative HSCT within the multicenter ALL-BFM-SCT 2003 trial for SI grade 3 or higher according to common terminology criteria for adverse events. A total 172 patients experienced at least one SI. Transplantation from matched unrelated donors (MUD) was associated with any type of SI in the pre-engraftment period (hazard ratio [HR]: 2.57; P < .001), and with any SI between day +30 and + 100 (HR: 2.91; P = .011). Bacterial (HR: 2.24; P = .041) and fungal infections (HR: 4.06; P = .057) occurred more often in the pre-engraftment phase and viral infections more often before day +30 (HR: 2.66; P = .007) or between day +30 and + 100 (HR: 3.89; P = .002) after HSCT from MUD as compared to matched sibling donors. Chronic GvHD was an independent risk factor for any type of SI after day +100 (HR: 2.57; P < .002). We conclude that allogeneic HSCT from MUD in children and adolescents with pediatric ALL is associated with higher infection rates, which seems attributable to an intensified GvHD prophylaxis including serotherapy and methotrexate.

Published
2019

25. Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study

Author

SCT patientenzorg, Child Health, Regenerative Medicine and Stem Cells, Balduzzi, Adriana, Dalle, Jean Hugues, Wachowiak, Jacek, Yaniv, Isaac, Yesilipek, Akif, Sedlacek, Petr, Bierings, Marc, Ifversen, Marianne, Sufliarska, Sabina, Kalwak, Krzysztof, Lankester, Arjan, Toporski, Jacek, Di Maio, Lucia, Glogova, Evgenia, Poetschger, Ulrike, Peters, Christina, SCT patientenzorg, Child Health, Regenerative Medicine and Stem Cells, Balduzzi, Adriana, Dalle, Jean Hugues, Wachowiak, Jacek, Yaniv, Isaac, Yesilipek, Akif, Sedlacek, Petr, Bierings, Marc, Ifversen, Marianne, Sufliarska, Sabina, Kalwak, Krzysztof, Lankester, Arjan, Toporski, Jacek, Di Maio, Lucia, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina

Published
2019

26. 92 - Incidence of Secondary Malignancies after Total Body Irradiation-Based Allogeneic HSCT in Children with ALL – Long-Term Follow-up from the Prospective ALL-SCT 2003 Trial

Author

Eichinger, Anna, Glogova, Evgenia, Poetschger, Ulrike, Bader, Peter, Basu, Oliver, Beier, Rita, Burkhardt, Birgit, Classen, Carl-Friedrich, Claviez, Alexander, Corbacioglu, Selim, Deubzer, Hedwig, Greil, Johann, Gruhn, Bernd, Gungor, Tayfun, Kafa, Kinan, Lang, Peter, Lange, Bjoern Soenke, Mueller, Ingo, Sauer, Martin G., Schlegel, Paul-Gerhard, Schulz, Ansgar, Stachel, Klaus Daniel, Strahm, Brigitte R., Wawer, Angela, Kühl, Jörn-Sven, Meisel, Roland, Peters, Christina, and Albert, Michael H.

Published
2022
Full Text
View/download PDF

27. Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.

Author

Lode, Holger N., primary, Valteau-Couanet, Dominique, additional, Gray, Juliet, additional, Luksch, Roberto, additional, Wieczorek, Aleksandra, additional, Castel, Victoria, additional, Ash, Shifra, additional, Laureys, Genevieve, additional, Papadakis, Vassilios, additional, Owens, Cormac, additional, Garaventa, Alberto, additional, Manzitti, Carla, additional, Siebert, Nikolai, additional, Troschke-Meurer, Sascha, additional, Glogova, Evgenia, additional, Poetschger, Ulrike, additional, and Ladenstein, Ruth Lydia, additional

Published
2019
Full Text
View/download PDF

28. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies : Impact of Disease Risk on Outcomes

Author

Dalle, Jean Hugues, Balduzzi, Adriana, Bader, Peter, Lankester, Arjan, Yaniv, Isaac, Wachowiak, Jacek, Pieczonka, Anna, Bierings, Marc, Yesilipek, Akif, Sedlaçek, Petr, Ifversen, Marianne, Sufliarska, Sabina, Toporski, Jacek, Glogova, Evgenia, Poetschger, Ulrike, Peters, Christina, Dalle, Jean Hugues, Balduzzi, Adriana, Bader, Peter, Lankester, Arjan, Yaniv, Isaac, Wachowiak, Jacek, Pieczonka, Anna, Bierings, Marc, Yesilipek, Akif, Sedlaçek, Petr, Ifversen, Marianne, Sufliarska, Sabina, Toporski, Jacek, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina

Published
2018

29. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes

Author

Stamceltransplantatieteam, SCT patientenzorg, Child Health, Regenerative Medicine and Stem Cells, PMC Medisch specialisten, Dalle, Jean Hugues, Balduzzi, Adriana, Bader, Peter, Lankester, Arjan, Yaniv, Isaac, Wachowiak, Jacek, Pieczonka, Anna, Bierings, Marc, Yesilipek, Akif, Sedlaçek, Petr, Ifversen, Marianne, Sufliarska, Sabina, Toporski, Jacek, Glogova, Evgenia, Poetschger, Ulrike, Peters, Christina, Stamceltransplantatieteam, SCT patientenzorg, Child Health, Regenerative Medicine and Stem Cells, PMC Medisch specialisten, Dalle, Jean Hugues, Balduzzi, Adriana, Bader, Peter, Lankester, Arjan, Yaniv, Isaac, Wachowiak, Jacek, Pieczonka, Anna, Bierings, Marc, Yesilipek, Akif, Sedlaçek, Petr, Ifversen, Marianne, Sufliarska, Sabina, Toporski, Jacek, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina

Published
2018

30. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial

Author

Kuhlen, M, Willasch, A, Dalle, J, Wachowiak, J, Yaniv, I, Ifversen, M, Sedlacek, P, Guengoer, T, Lang, P, Bader, P, Sufliarska, S, Balduzzi, A, Strahm, B, von Luettichau, I, Hoell, J, Borkhardt, A, Klingebiel, T, Schrappe, M, von Stackelberg, A, Glogova, E, Poetschger, U, Meisel, R, Peters, C, Kuhlen, Michaela, Willasch, Andre M., Dalle, Jean-Hugues, Wachowiak, Jacek, Yaniv, Isaac, Ifversen, Marianne, Sedlacek, Petr, Guengoer, Tayfun, Lang, Peter, Bader, Peter, Sufliarska, Sabina, Balduzzi, Adriana, Strahm, Brigitte, von Luettichau, Irene, Hoell, Jessica I., Borkhardt, Arndt, Klingebiel, Thomas, Schrappe, Martin, von Stackelberg, Arend, Glogova, Evgenia, Poetschger, Ulrike, Meisel, Roland, Peters, Christina, Kuhlen, M, Willasch, A, Dalle, J, Wachowiak, J, Yaniv, I, Ifversen, M, Sedlacek, P, Guengoer, T, Lang, P, Bader, P, Sufliarska, S, Balduzzi, A, Strahm, B, von Luettichau, I, Hoell, J, Borkhardt, A, Klingebiel, T, Schrappe, M, von Stackelberg, A, Glogova, E, Poetschger, U, Meisel, R, Peters, C, Kuhlen, Michaela, Willasch, Andre M., Dalle, Jean-Hugues, Wachowiak, Jacek, Yaniv, Isaac, Ifversen, Marianne, Sedlacek, Petr, Guengoer, Tayfun, Lang, Peter, Bader, Peter, Sufliarska, Sabina, Balduzzi, Adriana, Strahm, Brigitte, von Luettichau, Irene, Hoell, Jessica I., Borkhardt, Arndt, Klingebiel, Thomas, Schrappe, Martin, von Stackelberg, Arend, Glogova, Evgenia, Poetschger, Ulrike, Meisel, Roland, and Peters, Christina

Abstract

Relapse remains the major cause of treatment failure in children with high-risk acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem-cell transplantation (allo-SCT). Prognosis is considered dismal but data on risk factors and outcome are lacking from prospective studies. We analysed 242 children with recurrence of ALL after first allo-SCT enrolled in the Berlin-Frankfurt-Munster (BFM) ALL-SCT-BFM 2003 and ALL-SCT-BFM international 2007 studies. Median time from allo-SCT to relapse was 7·7 months; median follow-up from relapse after allo-SCT until last follow-up was 3·4 years. The 3-year event-free survival (EFS) was 15% and overall survival (OS) was 20%. The main cause of death was disease progression or relapse (86·5%). The majority of children (48%) received salvage therapy without second allo-SCT, 26% of the children underwent a second allo-SCT and 25% received palliative treatment only. In multivariate analyses, age, site of relapse, time to relapse and type of salvage therapy were identified as significant prognostic factors for OS and EFS, whereas factors associated with first SCT were not statistically significant. Combined approaches incorporating novel immunotherapeutic treatment options and second allo-SCT hold promise to improve outcome in children with post allo-SCT relapse.

Published
2018

31. Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trial

Author

Kuhlen, Michaela, primary, Bader, Peter, additional, Sauer, Martin, additional, Albert, Michael H., additional, Gruhn, Bernd, additional, Güngör, Tayfun, additional, Kropshofer, Gabriele, additional, Lang, Peter, additional, Lawitschka, Anita, additional, Metzler, Markus, additional, Pentek, Falk, additional, Rossig, Claudia, additional, Schlegel, Paul G., additional, Schrappe, Martin, additional, Schrum, Johanna, additional, Schulz, Ansgar, additional, Schwinger, Wolfgang, additional, von Stackelberg, Arend, additional, Strahm, Brigitte, additional, Suttorp, Meinolf, additional, Luettichau, Irene Teichert-von, additional, Wößmann, Wilhelm, additional, Borkhardt, Arndt, additional, Meisel, Roland, additional, Poetschger, Ulrike, additional, Glogova, Evgenia, additional, and Peters, Christina, additional

Published
2018
Full Text
View/download PDF

32. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial

Author

Kuhlen, Michaela, primary, Willasch, Andre M., additional, Dalle, Jean-Hugues, additional, Wachowiak, Jacek, additional, Yaniv, Isaac, additional, Ifversen, Marianne, additional, Sedlacek, Petr, additional, Guengoer, Tayfun, additional, Lang, Peter, additional, Bader, Peter, additional, Sufliarska, Sabina, additional, Balduzzi, Adriana, additional, Strahm, Brigitte, additional, von Luettichau, Irene, additional, Hoell, Jessica I., additional, Borkhardt, Arndt, additional, Klingebiel, Thomas, additional, Schrappe, Martin, additional, von Stackelberg, Arend, additional, Glogova, Evgenia, additional, Poetschger, Ulrike, additional, Meisel, Roland, additional, and Peters, Christina, additional

Published
2017
Full Text
View/download PDF

33. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood

Author

Aricò, Maurizio, Astigarraga, Itziar, Braier, Jorge, Donadieu, Jean, Gadner, Helmut, Glogova, Evgenia, Grois, Nicole, Henter, Jan-Inge, Janka, Gritta, McClain, Kenneth L., Ladisch, Stephan, Pötschger, Ulrike, Rosso, Diego, Thiem, Elfriede, Weitzman, Sheila, Windebank, Kevin, Minkov, Milen, and For the Histiocyte Society

Subjects
Pathology, medicine.medical_specialty, CIENCIAS MÉDICAS Y DE LA SALUD, Aspartate transaminase, Spleen, Medicina Clínica, Costal margin, Bone and Bones, Oncología, Langerhans cell histiocytosis, medicine, Humans, Bone lesion, Child, Proportional Hazards Models, Prognostic factor, biology, business.industry, Infant, Hematology, medicine.disease, Prognosis, Childhood, Multsystem disease, Histiocytosis, Haematopoiesis, Histiocytosis, Langerhans-Cell, medicine.anatomical_structure, Alanine transaminase, Child, Preschool, biology.protein, Bone involvement, business, Risck organ
Abstract

Skeletal involvement is generally, but not universally, characteristic of Langerhans cell histiocytosis (LCH). We investigated whether the presence of bone lesions at diagnosis is a prognostic factor for survival in LCH. Nine hundred and thirty-eight children with multisystem (MS) LCH, both high (386 RO+) and low (RO−) risk, were evaluated for bone lesions at diagnosis. Risk organ (RO+) involvement was defined as: haematopoietic system (haemoglobin 2 cm below the costal margin), liver (>3 cm and/or hypoproteinaemia, hypoalbuminaemia, hyperbilirubinaemia, and/or increased aspartate transaminase/alanine transaminase). Given the general view that prognosis in LCH worsens with increasing extent of disease, the surprising finding was that in MS+RO+ LCH the probability of survival with bone involvement 74 ± 3% (n = 230, 56 events) was reduced to 62 ± 4% (n = 156, 55 events) if this was absent (P = 0·007). An even greater difference was seen in the subgroup of patients with both liver and either haematopoiesis or spleen involvement: 61 ± 5% survival (n = 105; 52 events) if patients had bony lesions, versus 47 ± 5% (n = 111; 39 events) if they did not (P = 0·014). This difference was retained in multivariate analysis (P = 0·048). Although as yet unexplained, we conclude that bone involvement at diagnosis is a previously unrecognized favourable prognostic factor in MS+RO+ LCH. Fil: Aricò, Maurizio. Azienda Sanitaria Provinciale; Italia Fil: Astigarraga, Itziar. Bio Cruces Health Research Institute; España. Universidad del País Vasco; España Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina Fil: Donadieu, Jean. Hospital Trousseau; Francia Fil: Gadner, Helmut. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria Fil: Glogova, Evgenia. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria Fil: Grois, Nicole. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; Austria Fil: Henter, Jan-Inge. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia Fil: Janka, Gritta. University Medical Centre. Department of Haematology and Oncology; Alemania Fil: McClain, Kenneth L.. Texas Children's Cancer and Hematology Centers ; Estados Unidos Fil: Ladisch, Stephan. Children's National Medical Center ; Estados Unidos Fil: Pötschger, Ulrike. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria Fil: Rosso, Diego. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Thiem, Elfriede. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria Fil: Weitzman, Sheila. Hospital for Sick Children. Division of Hematology/Oncology; Canadá Fil: Windebank, Kevin. University of Newcastle; Reino Unido Fil: Minkov, Milen. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; Austria Fil: For the Histiocyte Society.

Published
2014

34. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?

Author

Pichler, Herbert, primary, Fritsch, Gerhard, additional, König, Margit, additional, Daxberger, Helga, additional, Glogova, Evgenia, additional, Pötschger, Ulrike, additional, Breuer, Sabine, additional, Lawitschka, Anita, additional, Güclü, Ece D., additional, Karlhuber, Susanne, additional, Holter, Wolfgang, additional, Haas, Oskar A., additional, Lion, Thomas, additional, and Matthes‐Martin, Susanne, additional

Published
2016
Full Text
View/download PDF

35. Risk Factors Affecting Outcome of Transplantation in Pediatric Acute Lymphoblastic Leukemia: Results of the International BFM ALL SCT Study

Author

Balduzzi, Adriana, primary, Dalle, Jean-Hugues, additional, Lankester, Arjan C, additional, Yaniv, Isaac, additional, Yesilipek, Akif, additional, Sedlacek, Petr, additional, Ifversen, Marianne, additional, Sufliarska, Sabina, additional, Bierings, Marc B, additional, Wachowiak, Jacek, additional, Toporski, Jacek, additional, Poetschger, Ulrike, additional, Glogova, Evgenia, additional, Hirsch, Ingeborg, additional, and Peters, Christina, additional

Published
2015
Full Text
View/download PDF

36. Presence of centromeric but absence of telomeric group B KIRhaplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL

Author

Babor, Florian, Peters, Christina, Manser, Angela R., Glogova, Evgenia, Sauer, Martin, Pötschger, Ulrike, Ahlmann, Martina, Cario, Gunnar, Feuchtinger, Tobias, Gruhn, Bernd, Güngör, Tayfun, Horn, Peter A., Kremens, Bernhard, Lang, Peter, Mezger, Markus, Müller, Ingo, Mytilineos, Joannis, Oevermann, Lena, Pichler, Herbert, Scherenschlich, Nadine, Schuster, Friedhelm R., Siepermann, Meinolf, Stachel, Daniel, Strahm, Brigitte, Wössmann, Wilhelm, Escherich, Gabriele, Zimmermann, Martin, Schrappe, Martin, Borkhardt, Arndt, Eckert, Cornelia, Bader, Peter, Uhrberg, Markus, and Meisel, Roland

Abstract

Although allogeneic hematopoietic stem-cell transplantation (HSCT) provides high cure rates for children with high-risk acute lymphoblastic leukaemia (ALL), relapses remain the main cause of treatment failure. Whereas donor killer cell immunoglobulin-like receptor (KIR) genotype was shown to impact on relapse incidence in adult myeloid leukaemia similar studies in paediatric ALL are largely missing. Effect of donor KIRgenotype on transplant outcome was evaluated in 317 children receiving a first myeloablative HSCT from an HLA-matched unrelated donor or sibling within the prospective ALL-SCT-BFM-2003 trial. Analysis of donor KIRgene polymorphism revealed that centromeric presence and telomeric absence of KIR Bhaplotypes was associated with reduced relapse risk. A centromeric/telomeric KIRscore (ct-KIRscore) integrating these observations correlated with relapse risk (hazard ratio (HR) 0.58; P= 0.002) while it had no impact on graft-versus-host disease or non-relapse mortality. In multivariable analyses ct-KIRscore was associated with reduced relapse risk (HR 0.58; P= 0.003) and a trend towards improved event-free survival (HR 0.76; P= 0.059). This effect proved independent of MRD level prior to HSCT. Our data suggest that in children with ALL undergoing HSCT after myeloablative conditioning, donor selection based on KIRgenotyping holds promise to improve clinical outcome by decreasing relapse risk and prolonged event-free survival.

Published
2019
Full Text
View/download PDF

37. Osteonecrosis after Allogeneic HSCT in Children with High-Risk or Relapsed ALL Treated in the ALL-SCT 2003 Trial

Author

Kuhlen, Michaela, Albert, Michael H., Bader, Peter, Ehlert, Karoline, Guengoer, Tayfun, Klingebiel, Thomas, Lang, Peter J., Schrappe, Martin, Schrum, Johanna, Schulz, Ansgar S., von Stackelberg, Arend, Strahm, Brigitte, Sykora, Karl-Walter, Teichert-von Luettichau, Irene, Borkhardt, Arndt, Meisel, Roland, Poetschger, Ulrike, Glogova, Evgenia, and Peters, Christina

Published
2017
Full Text
View/download PDF

38. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies

Author

Boztug, Heidrun, primary, Sykora, Karl-Walter, additional, Slatter, Mary, additional, Zecca, Marco, additional, Veys, Paul, additional, Lankester, Arjan, additional, Cant, Andrew, additional, Skinner, Roderick, additional, Wachowiak, Jacek, additional, Glogova, Evgenia, additional, Pötschger, Ulrike, additional, and Peters, Christina, additional

Published
2015
Full Text
View/download PDF

40. Solid Tumours

Author

Ladenstein R, Glogova E, Lanza F, Carreras E, Dufour C, Mohty M, and Kröger N

Abstract

In the absence of randomized prospective trials, the EBMT registry remains an important source to survey indications, outcome and clinical risk factors in patients with solid tumours treated by auto- and allo-HSCT., (Copyright 2019, EBMT and the Author(s).)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results